Patient and disease characteristics
| Characteristic . | Overall (N = 76) . |
|---|---|
| Age at infusion, y | |
| Mean (SD) | 10.4 (6.32) |
| Median (min, max) | 9.11 (0.838, 23.6) |
| Gender | |
| Female | 35 (46.1%) |
| Male | 41 (53.9%) |
| CAR T-cell product | |
| Investigational (NCT03573700) | 22 (28.9%) |
| Tisagenlecleucel | 54 (71.1%) |
| Disease status before CAR T-cell therapy | |
| Primary refractory | 15 (19.7%) |
| CR2 or less | 36 (47.4%) |
| Greater than CR2 | 24 (31.6%) |
| Missing | 1 (1.3%) |
| Pretreatment MRD (%)∗ | |
| Mean (SD) | 20.0 (30.2) |
| Median (min, max) | 2.00 (0, 100) |
| Characteristic . | Overall (N = 76) . |
|---|---|
| Age at infusion, y | |
| Mean (SD) | 10.4 (6.32) |
| Median (min, max) | 9.11 (0.838, 23.6) |
| Gender | |
| Female | 35 (46.1%) |
| Male | 41 (53.9%) |
| CAR T-cell product | |
| Investigational (NCT03573700) | 22 (28.9%) |
| Tisagenlecleucel | 54 (71.1%) |
| Disease status before CAR T-cell therapy | |
| Primary refractory | 15 (19.7%) |
| CR2 or less | 36 (47.4%) |
| Greater than CR2 | 24 (31.6%) |
| Missing | 1 (1.3%) |
| Pretreatment MRD (%)∗ | |
| Mean (SD) | 20.0 (30.2) |
| Median (min, max) | 2.00 (0, 100) |
CR, complete response; CR2, second complete response; max, maximum; min, minimum; SD, standard deviation.
In the bone marrow, using flow cytometry MRD testing; cohort included 2 patients with isolated extramedullary disease.